Compare IDEXX Laboratories, Inc. (IDXX) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Snowflake Inc — how do they compare? IDEXX Laboratories, Inc. trades at $553.81 (market cap $44.48B), while Snowflake Inc trades at $270.01 (market cap $95.09B). The key difference: Snowflake Inc is far larger — about 2.1× IDEXX Laboratories, Inc.'s market cap, and Snowflake Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | SNOW | |
|---|---|---|
Market Cap | $44.48B | $95.09B |
Sector | Health | Technology |
52-Week High | $766.68 | $280.16 |
52-Week Low | $520.87 | $121.11 |
Enterprise Value | $45.38B | $94.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Snowflake (SNOW) trades at $274.09, up 1.93% with bullish technical indicators and strong analyst support. The stock shows consistent earnings beats with Q1 2026 EPS of $0.39 exceeding expectations of $0.3193. Revenue growth remains robust at $3.63 billion in 2025, though the company continues to operate at a net loss of -$1.29 billion. Technical analysis indicates bullish momentum with current price near resistance at $274, while institutional sentiment remains positive with 81% buy ratings.
Snowflake presents a growth investment opportunity with accelerating AI Data Cloud adoption and 30% revenue growth targets, but faces significant execution risks from persistent losses and intense cloud competition. The consensus price target of $299.58 suggests 9% upside potential, though profitability challenges and high valuation multiples require careful monitoring of margin improvement trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
